"What does the competitive and scientific landscape look like?"
Who controls which cohort, and on what evidence. Drug-by-drug commercial posture, prescribing share and payer positioning.
Browse CI →Disease burden, diagnosis rates and the treatment pathway. The market map you build commercial strategy on.
Browse DL →A six-sheet KOL universe and engagement workbook, built gate by gate: sizing, tier classification, scientific influence, engagement readiness, MSL territory coverage, and cross-border network. Every KOL entry carries a verification tag.
Browse KOL →Lecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate.
Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs.
Rezdiffra and Wegovy now split the noncirrhotic MASH label. This is a Year 0 to Year 1 access and retention fight, not a pre-launch window.
Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry.
How the US NSCLC population segments by histology and biomarker, where it is actually diagnosed and tested, and where the gap between diagnosis and treatment costs patients.
Tirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality.
Iptacopan oral pivot versus the anti-C5 IV class. Orphan-drug exclusion from IRA negotiation (US), NICE HST (UK) and SFDA lag (GCC).
PNH diagnosis pathway, FLAER flow-cytometry bottleneck and the treated-prevalent pool across US centres.
Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access.
From zero disease-specific drugs to five in three years: how endothelin, complement and APRIL inhibitors are redrawing the IgAN market.
The prophylaxis class is fracturing along route: oral berotralstat and the first oral on-demand agent against a still-injectable antibody field.
Tafamidis's ATTR-CM monopoly meets acoramidis — while the orphan-drug exclusion keeps the stabilizer class out of IRA price negotiation.
The ATTR-CM vs ATTR-PN split, the wild-type/hereditary divide, and why Tc-PYP scintigraphy, not biopsy, is now the diagnostic gate for a largely undiagnosed population.
HAE pathophysiology, the Type I/II split, attack burden and the diagnostic-delay problem that defines the US in-market landscape.
US IgA nephropathy epidemiology, the biopsy-and-proteinuria diagnostic gate, and the shift from RAS-blockade supportive care to five disease-modifying therapies.
Three novel mechanisms in 24 months — FcRn antagonists vs C5 inhibitors, and the AChR+ vs MuSK+ line that segments the market.
Neuromuscular-junction autoantibody biology, the AChR/MuSK/seronegative split, and the crisis burden that defines US gMG.
Two Dec-2023 gene therapies (Casgevy, Lyfgenia) reset a ~100,000-patient market, while voxelotor's 2024 withdrawal thins the oral field.
Two next-generation ERTs, avalglucosidase alfa and cipaglucosidase alfa plus miglustat, move to displace alglucosidase alfa across the US late-onset Pompe market.
Five FDA-approved Gaucher type 1 therapies (three IV enzyme replacement vs two oral substrate reduction) and eliglustat's oral first-line pivot.
SMN1/SMN2 biology, the Type 1–4 severity spectrum, and how newborn screening splits SMA into pre-symptomatic and symptomatic populations.
US incidence 1 in 15,700, de novo SCN1A genetics, and one of the highest SUDEP rates documented in epilepsy.
Sutimlimab (Enjaymo) is the only FDA-approved CAD therapy — competing against off-label rituximab-based standard of care, not a branded rival.
GAA-deficiency biology, the LOPD-versus-IOPD split, the years-long diagnostic delay, and newborn screening across the US Pompe population.
SCD epidemiology, genotype mix, VOC and organ-damage burden, and the 22-year life-expectancy gap across the US in-market population.
A rare classical-complement autoimmune hemolytic anemia driven by cold-reactive IgM — primary CAD vs cold agglutinin syndrome, and the US hemolysis burden.
Three mechanisms, one SMN target — a one-time $2.125M gene therapy versus chronic intrathecal ASO and daily oral, and newborn screening resets the battlefield.
Two IV enzyme replacement therapies meet an oral chaperone that only ~35–50% of patients can take — and pegunigalsidase now challenges Fabrazyme's two-decade lead.
Gaucher type 1 epidemiology, the Ashkenazi Jewish founder burden, GBA1 genotype–phenotype, and the 20-fold Parkinson's risk.
Fenfluramine leads on efficacy, cannabidiol anchors the lower-cost branded option, and stiripentol holds the adjunct niche.
Classic childhood-onset Fabry versus a largely undiagnosed later-onset cardiac form, an X-linked organ timeline, and the ~35–50% amenable-mutation treatment gate.
The MASLD-to-MASH-to-F2-F3 funnel, NASH-CRN fibrosis staging, and the FIB-4-to-elastography diagnostic gap behind the 6.7M label-eligible pool.
US atopic dermatitis epidemiology — 16.5M adults, the moderate-to-severe pool, and the atopic march that frames the biologic-eligible segment.
38.4M US adults, an 8.7M undiagnosed pool, and complication burden driving GLP-1 and SGLT2 organ-protection strategy.
US Alzheimer's staging, the amyloid-confirmation diagnostic pathway, and the FDA-cleared plasma pTau-217 blood test resizing the addressable pool.
US adult obesity at 41.9% (CDC NHANES). BMI-class distribution, severe-obesity burden, and the comorbidity segments that drive coverage.
The COPD maintenance fight has moved past the inhaler. Two 2024 approvals, ensifentrine and dupilumab, opened the first genuinely novel mechanisms in a decade and split the market into an inhaler base and a biology-defined add-on tier.
COPD is a large, under-diagnosed, exacerbation-driven US disease that has just become biomarker-stratified. The blood eosinophil count now decides which of ~14 million diagnosed adults can reach a biologic.
Six mechanisms now compete for moderate-to-severe plaque psoriasis in the US: IL-17A, dual IL-17A/F, IL-23p19, IL-12/23, TNF and oral TYK2, and the efficacy bar has moved from PASI 75 to PASI 90.
Psoriasis affects about 3.0% of US adults, roughly 7.55 million people, but only the moderate-to-severe minority reaches the systemic and biologic therapies that define the commercial market.
First-line HR+/HER2- metastatic disease is a three-way CDK4/6-inhibitor contest, but only ribociclib has posted consistent overall-survival wins (63.9 vs 51.4 months in MONALEESA-2, HR 0.76). The real competition has moved downstream, where 2023 approvals of an oral SERD and an AKT inhibitor carve the post-CDK4/6 line by biomarker.
HR+/HER2- is the largest breast cancer subtype, roughly 68% of the estimated 317,000 new US invasive female cases in 2025. Most present early and are curable, but 20-30% recur to metastatic disease where five-year survival falls to about a third, making biomarker testing (ESR1, PIK3CA) the fork that determines the treatment path.
Tafamidis's ATTR-CM franchise meets acoramidis under NICE — which now tells clinicians to pick the least-expensive stabiliser.
Anti-C5 IV therapy holds the GCC PNH market under NPHC/MOH specialist-centre gating, while iptacopan's 82.3% haemoglobin-response rate has not reached a single GCC formulary.
Novel IgAN agents are newly registered across the GCC but not yet formulary-listed — nephrology specialist centres and the private hospital market are the fastest access channel while biopsy capacity limits diagnosis.
GCC HAE management is acute-only — prophylaxis penetration is near zero, more than 85% of patients are undiagnosed, and NPHC coverage for lanadelumab would be the access trigger for the region's largest market.
Tafamidis is SFDA-registered and tender-priced 80-90% below US list, but ATTR-CM in the GCC is a pre-commercial opportunity gated by Tc-PYP scintigraphy availability at fewer than 8 centres, not by drug access.
GCC Dravet prescribing runs opposite the US/EU hierarchy: cannabidiol is de-facto inaccessible under narcotics law, so stiripentol, not cannabidiol, is the de-facto specialist standard of care.
The UK Pompe Consortium's shared-care network, a 3–8 year late-onset diagnostic delay, and the ~25% inadequate-ERT-responder subset defining the next-generation enzyme-replacement opportunity.
GCC carries one of the highest per-capita SCD burdens globally: ~140,000 patients in Saudi Arabia alone. Both novel disease-modifiers hit regulatory trouble in 2023-2024, leaving a 25-year-old generic as the only agent with a stable market position.
A ~4,000-patient UK gMG treatment gap, NHS neuromuscular network diagnostics, and efgartigimod's June 2025 NICE rejection (TA1069) that leaves the access gap unresolved.
Nexviazyme beat Lumizyme on 6-minute-walk distance in COMET — but NPHC hasn't set switch criteria, so 80-120 GCC ERT patients mostly stay on the 2006-era standard.
Cannabidiol and fenfluramine anchor the NHS-commissioned NICE algorithm; stiripentol still holds a backbone role. New entrants must beat an entrenched three-drug sequence, not just show efficacy.
Oral migalastat versus IV enzyme replacement, and how pegunigalsidase's newly NICE-recommended suboptimal-responder appraisal (TA915) reshapes NHS-commissioned Fabry therapy.
Efgartigimod reached GCC neurology centres via SFDA/MOH UAE registration in 2023 — but NPHC formulary criteria for the FcRn class don't yet exist, so pyridostigmine and steroids still treat 85%+ of patients.
Crizanlizumab's EMA/MHRA withdrawal leaves a VOC-prevention gap. Casgevy's NICE recommendation is the watershed NHS gene-therapy access event — Lyfgenia has no UK regulatory status.
A single five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors. That kind of coordinated, multi-centre evidence generation is exactly the institutional signal this workbook sizes before any individual name enters it.
Avalglucosidase's NICE recommendation (TA821) versus entrenched alglucosidase alfa. NHS switch criteria and the Pombiliti queue position define the next 18 months of UK access.
NICE-commissioned tafamidis access (TA696, updated by TA984), a 30-centre Tc-PYP diagnostic pathway, and vutrisiran's TA868 PAS-backed approval reshaping UK ATTR identification and treatment.
England's NICE has issued three positive technology appraisals funding HAE prophylaxis since 2019 (TA606, TA738, TA1101), but the two newest MHRA-licensed agents, donidalorsen and sebetralstat, remain in NICE appraisal with no confirmed final NHS funding decision.
SCN1A molecular confirmation gap, the cannabidiol regulatory restriction, and the stiripentol-backbone standard of care across GCC paediatric neurology.
Six NHS centres, Great Ormond Street, Bristol, Alder Hey, Birmingham Children's, Leeds, and Newcastle, concentrate the UK's refractory Dravet syndrome cohort, and the British Paediatric Neurology Association's Dravet working group shapes NICE evidence review 18-24 months ahead of submission. That institutional network is what this workbook sizes first, not a roster of named physicians.
Five NHS specialist centres, Sheffield, Cambridge, Birmingham, Guy's and St Thomas', and Manchester, manage more than 90% of UK HAE patients. That concentration is what this workbook sizes before any physician enters the K1-K6 gate structure.
KFSH&RC, AUH, and Hamad Medical Corporation anchor a GCC HAE specialist community that SACIA sizes at just 6-10 physicians regionwide. That concentration is exactly what this workbook sizes before any individual name enters it.
Five named NHS lysosomal storage disorder centres, and Royal Free London's National Fabry Service, named NICE's appointed clinical expert for both migalastat's HST4 and pegunigalsidase alfa's TA915. That repeated appointment is exactly the institutional signal this workbook sizes before any individual name enters it.
The National Amyloidosis Centre holds the clinical-expert seat at every NICE ATTR appraisal to date. This workbook sizes the UK ATTR KOL network before a name enters it: NAC's 400-500-patient ATTRv surveillance registry, the separate UCL and Queen Elizabeth Hospital Birmingham National ATTRv Registry tracking approximately 800 patients, and the roughly 30 NHS centres running Tc-PYP scintigraphy nationally.
KFSH&RC runs the only HEK293 amenable-mutation assay in the GCC, and its formulary committee recommendation drives NPHC coverage decisions for every Fabry disease treatment. That kind of single-institution gatekeeping is exactly the concentration this workbook sizes before any individual name enters it.
The Renal Association's IgAN guideline committee, not any single physician, sets the clinical reference point NICE checks technology appraisals against. This workbook sizes that committee and the network behind it before individual outreach begins.
A 30-centre NHS neuromuscular network coordinated through Muscular Dystrophy UK, plus a 3,000-member Myasthenia Gravis Association UK patient registry, is the institutional signal this workbook sizes before any individual name enters it.
KFSH&RC maintains the only GCC-wide ATTRv genetic registry and houses the region's nuclear cardiology programme. Fewer than 8 named cardiology and scintigraphy centres region-wide, spanning KAMC, AUH, HMC Doha, and OCCI Muscat, define a small institutional field this workbook sizes before any individual name enters it.
GCC IgA nephropathy expertise concentrates in five named tertiary centres and roughly 300 practicing nephrologists, of whom 30 to 50 carry glomerular-disease subspecialty interest. This workbook sizes that concentrated institutional base before any individual name enters it.
Four London teaching hospitals, Barts, King's, Imperial, and Homerton, anchor roughly 6,000 of the UK's 15,000-17,000 sickle cell patients, with Birmingham Heartlands, Manchester, Bristol, and Nottingham forming the next concentration ring. That eight-centre structure is exactly the institutional signal this workbook sizes before any individual name enters it.
Just 8-10 to 10-15 neuromuscular neurologists across six named GCC referral centres manage 70-80% of confirmed generalised myasthenia gravis. That concentration is exactly what this workbook sizes before any individual name enters it.
A five-centre UK Pompe Consortium and an eight-centre NHS Highly Specialised Service network concentrate expertise around a six-physician BIMDG subcommittee that advises NICE directly. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
Four NHS Highly Specialised Services networks and six designated gene-therapy centres carry the UK SMA treatment pathway. This workbook sizes that institutional structure, plus the Bristol Institute of Child Health attenuation-cohort follow-up, before any physician name enters it.
KFSH&RC, KAMC, and AUH are the only GCC institutions running structured adult sickle cell disease programmes across a population of 200,000-250,000 patients. That three-centre concentration, anchored by the KFSH&RC Dammam flagship and 12+ MOH regional centres in Eastern Province, is exactly the institutional signal this workbook sizes before any individual name enters it.
Four designated GCC centres, KAMC, KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi, carry nearly all regional SMA gene-therapy and specialist referral activity. This workbook sizes that institutional concentration before any individual name enters it.
Six to eight named metabolic centres across the GCC hold enzyme replacement therapy infusion capacity for Pompe disease, led by KFSH&RC's roughly 120-patient, 15-year treatment experience. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
Seven institutions across Riyadh, Jeddah, Dubai, and Abu Dhabi concentrate the GCC's confirmed PNH caseload, and just 5 to 8 physicians function as genuine adoption gatekeepers. That kind of concentration is exactly what this workbook sizes before any individual name enters it.
The newborn screening expansion for infantile-onset Pompe, the late-onset limb-girdle diagnostic detour, and the ERT infusion access gap across GCC metabolic centres.
Five NHS Highly Specialised Services centres, anchored by the Leeds National PNH Service, concentrate fewer than 25 consultants managing over 90% of the UK's PNH caseload. That kind of institutional concentration is exactly the signal this workbook sizes before any individual name enters it.
GCC SMA incidence running 1:6,000–8,000 births, newborn screening now covering up to 90% in leading states, and an 800–1,200-patient pre-NBS-era Type 2/3 cohort defining the chronic-therapy opportunity.
Saint-Louis Hospital anchors France's MaRIH-coordinated PNH reference network of 14 competence centres, but only 24 of the 50-plus centres in the national clone-observatory network actively report into it. That kind of institutional structure is exactly what this workbook sizes before any individual name enters it.
The thyroid-disease diagnostic confounder, specialist neurologist concentration, and the FcRn antagonist access pathway across GCC neurology practice.
UK Renal Registry data, the ACEi/ARB-first Renal Association pathway, and the NHS economic case for novel agents built on £40–50M annual ESRD cost.
All three SMA therapies cleared NICE with confidential PAS. The UK's 2021 newborn screening programme is now the real access lever, shifting competition to physician and family preference.
HAE family cascade screening opportunity, laryngeal attack burden, and the prophylactic therapy access gap across GCC specialist centres.
UK HAE Alliance genetic testing, an 87% attack-rate reduction on lanadelumab, and the NICE TA606 prophylaxis standard defining NHS management.
Europe's largest SCD population at 15,000–17,000 patients, near-universal newborn-screening diagnosis since 1999, and NICE's recommendation of Casgevy (TA1044) as the gene therapy that will define UK access to a functional cure.
All three SMA mechanisms are formulary-listed in GCC — and outcomes-based rebate contracts now anchor Zolgensma's ~$1.5-1.8M price to a 24-month motor-milestone, following an NBS expansion generating 60-80 new gene-therapy candidates a year.
Premarital screening impact, the adult transition care gap, and the gene therapy access horizon across one of the world's highest per-capita SCD burdens.
Arabian Peninsula founder mutations, the female diagnosis gap, and the HEK assay bottleneck limiting oral chaperone therapy access across the GCC.
All three UK PNH agents have cleared NICE via the standard Technology Appraisal route: ravulizumab (TA698), iptacopan (TA1000), and crovalimab. Convenience and switch dynamics, not pathway-driven affordability, now determine NHS share.
IgAN diabetes-masking effect, the kidney biopsy bottleneck, and the ESRD progression gap across GCC nephrology practice.
NHS GMS free SCN1A testing, a NICE-defined CBD-then-fenfluramine algorithm, and 25 paediatric epilepsy HSS centres running the most treatment-advanced Dravet pathway in Europe.
The NHS lysosomal-storage-disorder specialist network, UK Fabry Outcome Survey longitudinal data, and both NHS-commissioned ERT and NICE HST4-recommended oral chaperone therapy across an estimated 800-patient UK cohort.
PNH diagnostic pathway, FLAER flow-cytometry bottleneck and the undiagnosed clonal pool across GCC specialist centres.
Germany has no confirmed PNH prevalence data of its own. The DGHO's Onkopedia guideline borrows an estimate from British and French registries, and diagnosis funnels through just two national referral centres.
France's own national hospitalization database puts PNH prevalence near 1 in 94,000, 897 patients from 2018 to 2022, lower than the 16-per-million figure Germany's DGHO Onkopedia guideline borrows from French and UK registries.
Iptacopan's orphan-drug status let it clear AMNOG with an established additional benefit and a substantial quality-of-life finding. Ravulizumab, tested on Germany's only PNH-specific G-BA review to date, found no added benefit at all.
A 9,146-patient US real-world study found no significant survival difference between palbociclib, ribociclib, and abemaciclib. When the drugs perform equivalently, KOL guidance decides which one gets prescribed, not clinical data.
Leeds National Registry data, FLAER access without referral, and the 30% PNH-aplasia overlap defining the NHS commercial picture.
GCC is a two-ERT Fabry market (agalsidase alfa via the EMA pathway alongside agalsidase beta), while migalastat's oral advantage, covering 35-50% of patients, is bottlenecked by the single GCC lab that can run the amenable-mutation assay.
No novel biologic is yet NHS-commissioned for generalised MG. Eculizumab's manufacturer withdrew its 2020 NICE appraisal before a verdict, and NICE rejected efgartigimod outright in 2025 — leaving rozanolixizumab as the FcRn class's last untested NICE bid.
Europe's first national SMA newborn-screening programme, all three therapies NICE-recommended with commercial arrangements, and a living UK cohort of ~1,000 patients across four disease types.
HAS restricted iptacopan to second-line use only, anemic patients with haemoglobin below 10 g/dL after at least six months on an anti-C5 inhibitor, and rated it ASMR III. Ravulizumab holds the first-line position with SMR important.
Two novel agents in Named Patient access ahead of NICE decisions — and the £20,000-30,000/QALY standard threshold both must clear, since IgAN doesn't qualify for the ultra-rare HST track.
ATTR-CM diagnostic abyss, Arabian Peninsula TTR variant registry, and the referral-pathway delay across GCC cardiology centres.
A five-institution Saudi pediatric neurology consortium spanning Riyadh, Jeddah, and Dammam tracked 44 Dravet syndrome patients on stiripentol combination therapy. That kind of coordinated, cross-city publication is exactly the institutional signal this workbook sizes before any individual name enters it.